Estrogen receptor-positive, progesterone receptor-negative breast cancer: Association with growth factor receptor expression and tamoxifen resistance

Journal of the National Cancer Institute

Volumn 97, Issue 17, 2005, Pages 1254-1261

  Arpino, Grazia ^a   Weiss, Heidi ^a   Lee, Adrian V ^a   Schiff, Rachel ^a   De Placido, Sabino ^b   Osborne, C Kent ^a   Elledge, Richard M ^a  

^a HOUSTON METHODIST HOSPITAL   (United States)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; GROWTH FACTOR RECEPTOR; PROGESTERONE RECEPTOR; TAMOXIFEN; TUMOR MARKER; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

ADULT; ANEUPLOIDY; ARTICLE; BREAST CANCER; CALCULATION; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CELL CYCLE S PHASE; CLINICAL FEATURE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FREQUENCY ANALYSIS; GENE OVEREXPRESSION; HAZARD ASSESSMENT; HUMAN; HUMAN CELL; HUMAN TISSUE; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MOLECULAR BIOLOGY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGRESSION ANALYSIS; SIGNAL TRANSDUCTION; STATISTICAL ANALYSIS; TUMOR VOLUME; ADJUVANT CHEMOTHERAPY; AGED; BREAST TUMOR; CHEMISTRY; DISEASE FREE SURVIVAL; DRUG RESISTANCE; GENE EXPRESSION REGULATION; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL; RISK; TREATMENT OUTCOME; UPREGULATION;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CONFIDENCE INTERVALS; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MIDDLE AGED; ODDS RATIO; PROPORTIONAL HAZARDS MODELS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TAMOXIFEN; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 24744443547     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/dji249     Document Type: Article

References (45)

1. Horwitz KB, McGuire WL. Specific progesterone receptors in human breast cancer. Steroids 1975;25:497-505.
2. Horwitz KB, Koseki Y, McGuire WL. Estrogen control of progesterone receptor in human breast cancer: Role of estradiol and antiestrogen. Endocrinology 1978;103:1742-51.
3. Horwitz KB, McGuire WL. Estrogen control of progesterone receptor in human breast cancer. J Biol Chem 1978;253:2223-8.
4. Hull DF, Clark GM, Osborne CK, Chamness GC, Knight WA, McGuire WL. Multiple estrogen receptor assays in human breast cancer. Cancer Res 1983;43:413-6.
5. Gross GE, Clark GM, Chamness GC, McGuire WL. Multiple progesterone receptor assays in human breast cancer. Cancer Res 1984;44:836-40.
6. Balleine RL, Earl MJ, Greenberg ML, Clarke CL. Absence of progesterone receptor associated with secondary breast cancer in postmenopausal women. Br J Cancer 1999;79:1564-71.
7. Bardou VJ, Arpino G, Elledge RM, Osborne CK, Clark GM. Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. J Clin Oncol 2003;21:1973-9.
8. McGuire WL. Hormone receptors: Their role in predicting prognosis and response to endocrine therapy. Semin Oncol 1978;5:428-33.
9. Elledge RM, Green S, Pugh R, Allred DC, Clark GM, Hill J, et al. Estrogen receptor (ER) and progesterone receptor (PgR), by ligand-binding assay compared with ER, PgR and pS2, by immuno-histochemistry in predicting response to tamoxifen in metastatic breast cancer: A Southwest Oncology Group Study. Int J Cancer 2000;89:111-7.
10. Ravdin PM, Green S, Dorr TM, McGuire WL, Fabian C, Pugh RP, et al. Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: Results of a prospective Southwest Oncology Group study. J Clin Oncol 1992;10:1284-91.
11. Osborne CK, Yochmowitz MG, Knight WA 3rd, McGuire WL. The value of estrogen and progesterone receptors in the treatment of breast cancer. Cancer 1980;46(12 Suppl):2884-8.
12. De Placido S, Gallo C, Marinelli A, Perrone F, Pagliarulo G, Petrella G, et al. Steroid hormone receptor levels and adjuvant tamoxifen in early breast cancer. Ten year results of the Naples (GUN) Study. Breast Cancer Res Treat 1990;16:111-7.
13. McGuire WL. Steroid receptors in human breast cancer. Cancer Res 1978;38(11 Pt 2):4289-91.
14. Dowsett M, on behalf of the ATAC Trialist Group. Analysis of time to recurrence in the ATAC (arimidex, tamoxifen, alone or in combination) trial according to estrogen receptor and progesterone receptor status. Breast Cancer Res Treat 2003;82(Suppl 1):S7.
15. Singh A, Ali S, Kothari MS, De Bella MT, Smith C, Timms E, et al. Reporter gene assay demonstrates functional differences in estrogen receptor activity in purified breast cancer cells: A pilot study. Int J Cancer 2003;107:700-6.
16. Konecny G, Pauletti G, Pegram M, Untch M, Dandekar S, Aguilar Z, et al. Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer. J Natl Cancer Inst 2003;95:142-53.
17. Dowsett M, Bundred NJ, Decensi A, Sainsbury RC, Lu Y, Hills MJ, et al. Effect of raloxifene on breast cancer cell Ki67 and apoptosis: A double-blind, placebo-controlled, randomized clinical trial in postmenopausal patients. Cancer Epidemiol Biomarkers Prev 2001;10:961-6.
18. Bamberger AM, Milde-Langosch K, Schulte HM, Loning T. Progesterone receptor isoforms, PR-B and PR-A, in breast cancer: Correlations with clinicopathologic tumor parameters and expression of AP-1 factors. Horm Res 2000;54:32-7.
19. Arpino G, Green SJ, Allred DC, Lew D, Martino S, Osborne CK, et al. HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: A southwest oncology group study. Clin Cancer Res 2004;10:5670-6.
20. Cui X, Zhang P, Deng W, Oesterreich S, Lu Y, Mills GB, et al. Insulin-like growth factor-I inhibits progesterone receptor expression in breast cancer cells via the phosphatidylinositol 3-kinase/Akt/ mammalian target of rapamycin pathway: Progesterone receptor as a potential indicator of growth factor activity in breast cancer. Mol Endocrinol 2003;17:575-88.
21. Cormier EM, Wolf MF, Jordan VC. Decrease in estradiol-stimulated progesterone receptor production in MCF-7 cells by epidermal growth factor and possible clinical implication for paracrine-regulated breast cancer growth. Cancer Res 1989;49:576-80.
22. Petz LN, Ziegler YS, Schultz JR, Nardulli AM. Fos and Jun inhibit estrogen-induced transcription of the human progesterone receptor gene through an activator protein-1 site. Mol Endocrinol 2004;18:521-32.
23. Shou J, Massarweh S, Osborne CK, Wakeling AE, Ali S, Weiss H, et al. Mechanisms of tamoxifen resistance: Increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst 2004;96:926-35.
24. Nicholson RI, Gee JM. Oestrogen and growth factor cross-talk and endocrine insensitivity and acquired resistance in breast cancer. Br J Cancer 2000;82:501-13.
25. Schafer JM, Bentrem DJ, Takei H, Gajdos C, Badve S, Jordan VC. A mechanism of drug resistance to tamoxifen in breast cancer. J Steroid Biochem Mol Biol 2002;83:75-83.
26. Osborne CK, Bardou V, Hopp TA, Chamness GC, Hilsenbeck SG, Fuqua SA, et al. Role ofthe estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst 2003;95:353-61.
27. Harris JR. Diseases of the breast, 3rd edition. Philadelphia (PA): Lippincott, Williams & Wilkins; 2004.
28. McGuire WL, De La Garza M, Chamness GC. Evaluation of estrogen receptor assays in human breast cancer tissue. Cancer Res 1977;37:637-9.
29. Powell B, Garola RE, Chamness GC, McGuire WL. Measurement of progesterone receptor in human breast cancer biopsies. Cancer Res 1979;39: 1678-82.
30. Clark GM, Osborne CK, McGuire WL. Correlations between estrogen receptor, progesterone receptor and patient characteristics in human breast cancer. J Clin Oncol 1984;2:1102-9.
31. Wenger CR, Clark GM. S-phase fraction and breast cancer - a decade of experience. Breast Cancer Res Treat 1998;51:255-65.
32. Ciocca DR, Fujimura FK, Tandon AK, Clark GM, Mark C, Lee-Chen GJ, et al. Correlation of HER-2/neu amplification with expression and with other prognostic factors in 1103 breast cancers. J Natl Cancer Inst 1992;84:1279-82.
33. Tandon AK, Clark GM, Chamness GC, Ullrich A, McGuire WL. HER-2/neu oncogene protein and prognosis in breast cancer. J Clin Oncol 1989;7:1120-8.
34. Klijn JG, Berns PM, Bontenbal M, Foekens JA. Growth factors. Clinical implications in breast cancer. Ann N Y Acad Sci 1993;698:85-101.
35. Klijn JG, Berns PM, Schmitz PI, Foekens JA. The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: A review on 5232 patients. Endocr Rev 1992;13:3-17.
36. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244:707-12.
37. Huang H, Neven P, Drijkoningen M, Paridaens R, Wildiers H, Van Limbergen E, et al. Association between tumor characteristics and HER-2/neu by immunohistochemistry in 1362 women with primary operable breast cancer. J Clin Pathol 2005;58:611-6.
38. Huang HJ, Neven P, Drijkoningen M, Paridaens R, Wildiers H, Van Limbergen E, et al. Association between HER-2/neu and the progesterone receptor in oestrogen-dependent breast cancer is age-related. Breast Cancer Res Treat 2005;91:81-7.
39. Petz LN, Ziegler YS, Schultz JR, Kim H, Kemper JK, Nardulli AM. Differential regulation of the human progesterone receptor gene through an estrogen response element half site and Sp1 sites. J Steroid Biochem Mol Biol 2004;88:113-22.
40. Carlomagno C, Perrone F, Gallo C, De Laurentiis M, Lauria R, Morabito A, et al. c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases. J Clin Oncol 1996;14:2702-8.
41. De Placido S, De Laurentiis M, Carlomagno C, Gallo C, Perrone F, Pepe S, et al. Twenty-year results of the Naples GUN Randomized Trial: predictive factors of adjuvant tamoxifen efficacy in early breast cancer. Clin Cancer Res 2003;9:1039-46.
42. Dowsett M, Harper-Wynne C, Boeddinghaus I, Salter J, Hills M, Dixon M, et al. HER-2 amplification impedes the antiproliferative effects of hormone therapy in estrogen receptor-positive primary breast cancer. Cancer Res 2001;61:8452-8.
43. Nicholson RI, McClelland RA, Gee JM, Manning DL, Cannon P, Robertson JE, et al. Epidermal growth factor receptor expression in breast cancer: association with response to endocrine therapy Breast Cancer Res Treat 1994;29:117-25.
44. Elledge RM, Green S, Ciocca D, Pugh R, Allred DC, Clark GM, et al. HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: A Southwest Oncology Group Study. Clin Cancer Res 1998;4:7-12.
45. Johnson MD, Westley BR, May FE. Oestrogenic activity of tamoxifen and its metabolites on gene regulation and cell proliferation in MCF-7 breast cancer cells. Br J Cancer 1989;59:727-38.